Skip to main content
Learn about biosimilar medications at

If you have arthritis, diabetes, kidney conditions, cancer, macular degeneration, or some chronic skin and bowel diseases, you may be using a biologic medication. Biologics are medications generally made from living sources like bacteria and yeast. These medications are often expensive — sometimes unaffordable. That’s where biosimilars might be able to help.

A biosimilar is a biologic that is highly similar to an original biologic already approved by the FDA. Both products are made from the same types of sources (such as living cells or microorganisms). This means biosimilars are as safe and effective as the original biologic for their approved uses. Biosimilars may also save you money.

If you’re concerned about cost, talk with your health care provider about switching to a biosimilar. To help you have a more meaningful conversation, the FTC and FDA developed the publication, Are you on a Biologic Medication? What to know about biosimilar treatment options. The publication helps answer common questions including:

  • Is a biosimilar the same as a generic?
  • Should I be concerned if my doctor prescribes a biosimilar?
  • What is the difference between a biosimilar and an interchangeable biosimilar?
  • Will my insurance cover a biosimilar?

The FTC and FDA also have released a joint Summary Report on the FDA/FTC Workshop on a Competitive Marketplace for Biosimilars held on March 9, 2020.

To learn more, visit For more information on health-related issues and advertising, visit

Search Terms

It is your choice whether to submit a comment. If you do, you must create a user name, or we will not post your comment. The Federal Trade Commission Act authorizes this information collection for purposes of managing online comments. Comments and user names are part of the Federal Trade Commission’s (FTC) public records system, and user names also are part of the FTC’s computer user records system. We may routinely use these records as described in the FTC’s Privacy Act system notices. For more information on how the FTC handles information that we collect, please read our privacy policy.

The purpose of this blog and its comments section is to inform readers about Federal Trade Commission activity, and share information to help them avoid, report, and recover from fraud, scams, and bad business practices. Your thoughts, ideas, and concerns are welcome, and we encourage comments. But keep in mind, this is a moderated blog. We review all comments before they are posted, and we won’t post comments that don’t comply with our commenting policy. We expect commenters to treat each other and the blog writers with respect.

  • We won’t post off-topic comments, repeated identical comments, or comments that include sales pitches or promotions.
  • We won’t post comments that include vulgar messages, personal attacks by name, or offensive terms that target specific people or groups.
  • We won’t post threats, defamatory statements, or suggestions or encouragement of illegal activity.
  • We won’t post comments that include personal information, like Social Security numbers, account numbers, home addresses, and email addresses. To file a detailed report about a scam, go to

We don't edit comments to remove objectionable content, so please ensure that your comment contains none of the above. The comments posted on this blog become part of the public domain. To protect your privacy and the privacy of other people, please do not include personal information. Opinions in comments that appear in this blog belong to the individuals who expressed them. They do not belong to or represent views of the Federal Trade Commission.

Cheryl Dailey
March 01, 2023

This raised more questions than it answered. What was the purpose if there is no intent to provide any information?

March 02, 2023

watching for other comments on this topic.

Buford Tatum
March 16, 2023

Dear administrator, Keep up the good work, admin!